In This Article:
European markets have recently shown resilience, with the STOXX Europe 600 Index climbing 2.77% amid easing trade tensions between the U.S. and China, providing a positive backdrop for investors. In such a climate, penny stocks—though an older term—remain relevant as they often represent smaller or less-established companies that can offer substantial value when backed by solid financials. By identifying those with strong balance sheets and clear growth potential, investors may uncover opportunities in this niche segment of the market.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Financial Health Rating |
| Bredband2 i Skandinavien (OM:BRE2) | SEK2.16 | SEK2.07B | ★★★★☆☆ |
| Transferator (NGM:TRAN A) | SEK2.60 | SEK237.06M | ★★★★★☆ |
| Angler Gaming (NGM:ANGL) | SEK3.75 | SEK281.19M | ★★★★★★ |
| Hifab Group (OM:HIFA B) | SEK3.70 | SEK225.1M | ★★★★★★ |
| Tesgas (WSE:TSG) | PLN2.59 | PLN29.4M | ★★★★★☆ |
| IMS (WSE:IMS) | PLN3.65 | PLN123.71M | ★★★★☆☆ |
| Cellularline (BIT:CELL) | €2.60 | €54.84M | ★★★★★☆ |
| Netgem (ENXTPA:ALNTG) | €0.97 | €32.48M | ★★★★★★ |
| Arcure (ENXTPA:ALCUR) | €3.955 | €22.9M | ★★★★☆☆ |
| Deceuninck (ENXTBR:DECB) | €2.21 | €305.12M | ★★★★★★ |
Click here to see the full list of 431 stocks from our European Penny Stocks screener.
Let's dive into some prime choices out of the screener.
Innate Pharma
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Innate Pharma S.A. is a biotechnology company focused on developing immunotherapies for cancer patients both in France and internationally, with a market cap of €153.21 million.
Operations: The company generates revenue from its biotechnology segment, amounting to €20.12 million.
Market Cap: €153.21M
Innate Pharma's recent financial performance highlights challenges typical of penny stocks, with a significant net loss of €49.47 million for 2024 and declining revenue from €61.64 million to €20.12 million year-over-year, indicating volatility in its earnings stream. Despite being unprofitable, the company maintains a strong cash position exceeding its total debt and has a cash runway exceeding three years based on current free cash flow. The recent completion of a €15 million equity offering suggests efforts to bolster financial stability amid ongoing development activities, including the FDA Breakthrough Therapy Designation for lacutamab targeting Sézary Syndrome, potentially enhancing future prospects.
Nurminen Logistics Oyj
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Nurminen Logistics Oyj offers logistics services across Finland, Russia, Sweden, and the Baltic countries with a market cap of €87.40 million.